-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Haemonetics, Lowers Price Target to $84

Benzinga·05/08/2025 18:53:18
Listen to the news
Needham analyst Mike Matson maintains Haemonetics (NYSE:HAE) with a Buy and lowers the price target from $104 to $84.